Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
IPO Year: 2015
Exchange: NASDAQ
Website: alpineimmunesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2024 | $55.00 | Buy | Guggenheim |
| 2/15/2024 | $44.00 | Outperform | Wolfe Research |
| 10/18/2023 | $18.00 | Buy | Berenberg |
| 10/17/2023 | $18.00 | Buy | Berenberg |
| 10/5/2023 | $19.00 | Outperform | RBC Capital Mkts |
| 6/26/2023 | $14.00 | Outperform | Oppenheimer |
| 1/19/2023 | $17.00 | Overweight | Morgan Stanley |
| 11/21/2022 | $15.00 | Outperform | SVB Leerink |